You are using an unsupported browser. Please switch to a different browser to get the best experience.
Promotional information from Santen for healthcare professionals only. Prescribing information can be found below.
UK: Prescribing information IE: Prescribing information

Adverse events should be reported. For UK: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Santen UK Limited (email: medinfo@santen.co.uk or telephone: 0345 075 4863). For Ireland: Reporting forms and information can be found at www.hpra.ie. Adverse events should also be reported to Santen UK Limited (email: medinfo@santen.co.uk or telephone: +353 1 695 0008).

Roclanda, with netarsudil, is the first innovation in the medical management of glaucoma for 25 years

About

Roclanda is a fixed-dose combination of latanoprost and netarsudil, a ROCK inhibitor1,2

Roclanda is indicated for the reduction of IOP in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.1

Roclanda is a fixed-dose combination of latanoprost and netarsudil that targets trabecular meshwork (TM) dysfunction without losing sight of IOP control.1,3-5

Click on the diagram below to view the Roclanda® MOA

Adapted from Goel M et al, 20106
PGA: prostaglandin analogue

Roclanda targets trabecular meshwork dysfunction lower IOP

Rock Inhibition
The Rho/ROCK pathway has demonstrated a role in IOP modulation; upregulation of this pathway causes an increase in outflow resistance and decrease in aqueous humour (AH) outflow due to cell rigidity, leading to a corresponding increase in IOP7,8
Roclanda therefore presents an opportunity to target primarily TM cellular dysfunction to promote trabecular outflow and reduce IOP3,7
The importance of netarsadil
Netarsudil is a ROCK inhibitor that has been shown to increase trabecular outflow in preclinical and clinical studies versus baseline9,3,10-13
Netarsudil primarily targets the TM dysfunction associated with primary open angle glaucoma (POAG)13, increasing outflow facility and resulting in a reduction in IOP versus baseline9,11,13

*Versus baseline.

See the evidence behind treatment with Roclanda >

Learn more about the trabecular meshwork >

Request Further Information

References
  1. Roclanda Summary of Product Characteristics
  2. Schehlein E M, Robin A L. Rho-associated kinase inhibitors: evolving strategies in glaucoma treatment. Drugs 2019;79(10):1031-1036
  3. Al-Humimat G, Marashdeh I et al. Investigational rho kinase inhibitors for the treatment of glaucoma. J Exp Pharmacol 2021;Volume 13:197-212
  4. Moshirfar M, Parker L et al. Use of Rho kinase inhibitors in ophthalmology: a review of the literature. Med Hypothesis Discov Innov Ophthalmol 2018;7(3):101-111
  5. Buffault J, Brignole-Baudouin F et al. The dual effect of Rho-kinase inhibition on trabecular meshwork cells cytoskeleton and extracellular matrix in an in vitro model of glaucoma. J Clin Med 2022;11(4):1001
  6. Goel M, Picciani R G et al. Aqueous humor dynamics: a review. Open Ophthalmol J 2010;4:52-59
  7. Buffault J, Labbé A et al. The trabecular meshwork: structure, function and clinical implications. A review of the literature. J Fr Ophtalmol 2020;43(7):e217-e230
  8. Ahmad S S, Zia-ur-Rahman S et al. Pharmacologic trabeculectomy – modulation of aqueous humor outflow through the trabecular meshwork. US Ophthalmic Rev 2015;8(1):46–51
  9. Rao P V, Pattabiraman P P, Kopczynski C. Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: bench to bedside research. Exp Eye Res 2017;158:23-32
  10. Sturdivant J M, Royalty S M et al. Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. Bioorganic Med Chem Lett 2016;26(10):2475-2480
  11. Ren R, Li G et al. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Investig Ophthalmol Vis Sci 2016;57(14):6197-6209
  12. Kazemi A, McLaren J W et al. The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharmacol Ther 2018;34(5):380-386
  13. Sit A J, Gupta D et al. Netarsudil improves trabecular outflow facility in patients with primary open angle glaucoma or ocular hypertension: a phase 2 study. Am J Ophthalmol 2021;226:262-269
  14. Stamer W D, Clark A F. The many faces of the trabecular meshwork cell. Exp Eye Res 2017;158:112-123

This site is for
Healthcare Professionals ONLY